SCHEMBL6490784

SCHEMBL6490784

Fc1ccc(-c2nn3ccccc3c2-c2cc(-c3ccccc3)nc(NC3CCCC3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.48
GSK3B P49841 2/20 0.47
MAPK14 Q16539 2/20 0.47
EGFR P00533 1/20 0.47
RAF1 P04049 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA2B P29275 1/20 0.47
ADORA1 P30542 1/20 0.47
MAPK8 P45983 6/20 0.43
MAPK9 P45984 6/20 0.43
AKT1 P31749 1/20 0.41
IGF1R P08069 2/20 0.41
VCP P55072 1/20 0.39
ALOX5 P09917 1/20 0.39
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
MAPK1 P28482 2/20 0.39
MAPK3 P27361 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453329 0.86 KDM4E (0.47) KDM4EGSK3BMAPK14ADORA1AKT1
SCHEMBL5455132 0.84 MAPK14 (0.48) KDM4EGSK3BMAPK14ADORA1AKT1
SCHEMBL5398657 0.81 MAPK9 (0.56) GSK3BMAPK14EGFRRAF1ADORA3
SCHEMBL5457541 0.80 KDM4E (0.42) KDM4EGSK3BMAPK14ADORA1AKT1
SCHEMBL6501891 0.80 MAPK14 (0.48) GSK3BMAPK14EGFRRAF1ADORA3
SCHEMBL5457552 0.79 KDM4E (0.51) KDM4EMAPK14EGFRMAPK8MAPK9
SCHEMBL14339923 0.79 KDM4E (0.41) KDM4EGSK3BMAPK14AKT1VCP
Hydrochloric Acid SCHEMBL5454770 0.79 KDM4E (0.50) KDM4EMAPK14EGFRMAPK8MAPK9
SCHEMBL5214203 0.77 MAPK9 (0.48) MAPK8MAPK9
SCHEMBL5214451 0.75 CSNK1D (0.51) GSK3BMAPK14MAPK8MAPK9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107400-A1 Use of pyrazolopyridines as therapeutic compounds SMITHKLINE BEECHAM CORPORATION 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107400-A1 Use of pyrazolopyridines as therapeutic compounds QDPR, DPYD, ENTPD5 KDM4E 3044/4885GSK3B 3047/4885MAPK14 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.